Current data and analytics capabilities are often times insufficient to identify and characterize precise patient cohorts and prescribers for targeted therapies. Learn how Clarify Health aided the launch of a second-line therapeutic in Acute Myeloid Leukemia (AML), and revamped this top pharma’s HCP target list to significantly increase the revenue potential of the product.
